Idorsia, Medincell, Ascelia Pharma
Idorsia: post hoc aprocitentan data at AHA Hypertension; Medincell: FDA approves Weltruza; Ascelia Pharma: Orviglance path after its FDA Type A meeting.
Idorsia, Medincell, Ascelia Pharma Beitrag lesen »
Genmab’s epcoritamab succeeds in frontline DLBCL
Also: Alvotech’s FDA capacity win, CSL–Alentis deal worth up to $1.6bn, new Idorsia data at AHA.
Genmab’s epcoritamab succeeds in frontline DLBCL Beitrag lesen »